Navigation Links
Preclinical Research on Coronary Stent with CeloNova BioSciences' Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
Date:9/8/2007

ATLANTA, Sept. 9 /PRNewswire/ -- Celonova Biosciences, Inc. ("CeloNova"), a leading developer of innovative medical devices, today announced that the paper, "Comparison of late in-stent stenosis and vessel wall inflammation in Cypher(R) Select(TM), Taxus(R) Express(TM), and Polyzene(R)-F nanocoated cobalt chromium stents in a porcine coronary artery model" prepared by Dr. Boris Radeleff has been chosen to receive the CIRSE 2007 Magna Cum Laude EPOS Award.

"We are delighted that Dr. Radeleff has been honored by his peers for his work comparing the performance of the leading drug-eluting stents to a stent treated with CeloNova's proprietary Polyzene(R)-F medically inert surface coating," said Thomas A. Gordy, CeloNova President and Chief Executive Officer. "This award validates the high quality of the work undertaken by Dr. Radeleff and his colleagues to understand how Polyzene(R)-F can enhance the performance of coronary stents by inhibiting restenosis and thrombus formation without the need to resort to an anti-proliferative drug or long-term dual antiplatelet medications. We continue to believe, based on this and other ongoing research, that Polyzene(R)-F represents a revolutionary breakthrough in the quest to develop the ideal long-term solution for coronary stenting."

Dr. Radeleff, a physician at the University Hospital of Heidelberg, received his award at the CIRSE Opening Ceremony and Awards Session in Athens, Greece on Saturday, September 08.

About CIRSE

The Cardiovascular and Interventional Radiological Society of Europe is a non-profit making, educational and scientific association of 2,300 interventional professionals with an active personal involvement and interest in interventional radiology or cardiovascular imaging techniques.

About CIRSE 2007

The CIRSE Annual Scientific and Postgraduate Educational Meeting has established itself as the premier gathering for all professionals devoted to the field of Cardiovascular and Interventional Radiology in Europe. CIRSE 2007 is a unique forum where medical professionals can meet their colleagues from all around the world, and exchange ideas and information in the field of minimally invasive, image guided therapies.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, and possesses both anti-bacterial and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes its Embozene(TM) Microspheres, used to treat arteriovenous malformations, hypervascularized tumors, uterine fibroids and hepatocellular carcinoma. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Contact: Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
3. Control Your siRNA Research
4. Getting Started with MicroRNA Research
5. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
6. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
7. Research Organics
8. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
9. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
10. Research Tools for Analysis of ZAP-70
11. Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control ... vendor-supported, portable online UHPLC, with robust, probe-based sampling. , Online liquid ...
(Date:12/2/2016)... --  SurePure, Inc. (OTCQB: SURP) a global leader ... concluded an agreement with Tamarack Biotics under which Tamarack ... acquire units of the Company,s patented photopurification technology with ... Concurrently with the option, SurePure has entered ... seek regulatory approvals in the United States ...
(Date:12/2/2016)... 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease tests, ... Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy representatives ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):